双侧肾缺如连续羊膜腔灌注后的新生儿生存:肾无羊水胎儿治疗试验
这项前瞻性非随机临床试验在9个美国胎儿治疗中心纳入21对确诊胎儿双侧肾缺如致无羊水的母胎,孕26周前开始连续羊膜腔灌注。试验因中期分析关注主要终点之外的新生儿患病与死亡而提前终止;17例活产中14例(82%)达到主要终点,仅6例(35%)存活至出院。
要点
- 孕26周前连续羊膜腔灌注可减轻致死性肺发育不良,但与早产相关。
- 17例活产中14例(82%)达到主要终点(出生后存活≥14天并放置透析通路)。
- 17例活产儿中仅6例(35%)存活至出院,出院时接受腹膜透析。
核心结论
- 连续羊膜腔灌注减轻了致死性肺发育不良,但与早产相关;出院存活率较低,凸显独立于肺功能的额外死亡负担。
研究设计与样本
- 前瞻性非随机临床试验,2018年12月至2022年7月在美国9个胎儿治疗中心开展。
- 报告21对确诊无羊水且胎儿为孤立性双侧肾缺如、未发现其他先天畸形的母胎结局。
主要发现
- 因中期分析18对母胎后关注主要终点之外的新生儿患病与死亡,试验提前终止。
- 17例活产(94%),分娩中位孕周为32周4天(IQR,32-34周);所有参与者均在孕37周前分娩。
- 17例活产儿中14例(82%)达到主要终点(95%CI,44%-99%)。
- 与达到主要终点生存相关的因素包括更多灌注次数(P=.01)、孕周大于32周(P=.005)和更高出生体重(P=.03)。
- 17例活产儿中仅6例(35%)存活至出院,出院时接受腹膜透析,中位年龄为生后24周(范围,12-32周)。
关键数值与推荐
- 主要终点为出生后存活至14天或更长并放置透析通路。
- 14例(82%)活产儿达到主要终点(95%CI,44%-99%)。
- 6例(35%)活产儿存活至出院,出院时接受腹膜透析,中位年龄为生后24周(范围,12-32周)。
局限性
- 试验因中期分析18对母胎后关注主要终点之外的新生儿患病与死亡而提前终止。
- 需要额外长期数据以全面描述存活新生儿的结局并评估患病与死亡负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Early anhydramnios during pregnancy, resulting from fetal bilateral renal agenesis, causes lethal pulmonary hypoplasia in neonates. Restoring amniotic fluid via serial amnioinfusions may promote lung development, enabling survival. OBJECTIVE: To assess neonatal outcomes of serial amnioinfusions initiated before 26 weeks' gestation to mitigate lethal pulmonary hypoplasia. DESIGN, SETTING, AND PARTICIPANTS: Prospective, nonrandomized clinical trial conducted at 9 US fetal therapy centers between December 2018 and July 2022. Outcomes are reported for 21 maternal-fetal pairs with confirmed anhydramnios due to isolated fetal bilateral renal agenesis without other identified congenital anomalies. EXPOSURE: Enrolled participants initiated ultrasound-guided percutaneous amnioinfusions of isotonic fluid before 26 weeks' gestation, with frequency of infusions individualized to maintain normal amniotic fluid levels for gestational age. MAIN OUTCOMES AND MEASURES: The primary end point was postnatal infant survival to 14 days of life or longer with dialysis access placement. RESULTS: The trial was stopped early based on an interim analysis of 18 maternal-fetal pairs given concern about neonatal morbidity and mortality beyond the primary end point despite demonstration of the efficacy of the intervention. There were 17 live births (94%), with a median gestational age at delivery of 32 weeks, 4 days (IQR, 32-34 weeks). All participants delivered prior to 37 weeks' gestation. The primary outcome was achieved in 14 (82%) of 17 live-born infants (95% CI, 44%-99%). Factors associated with survival to the primary outcome included a higher number of amnioinfusions (P = .01), gestational age greater than 32 weeks (P = .005), and higher birth weight (P = .03). Only 6 (35%) of the 17 neonates born alive survived to hospital discharge while receiving peritoneal dialysis at a median age of 24 weeks of life (range, 12-32 weeks). CONCLUSIONS AND RELEVANCE: Serial amnioinfusions mitigated lethal pulmonary hypoplasia but were associated with preterm delivery. The lower rate of survival to discharge highlights the additional mortality burden independent of lung function. Additional long-term data are needed to fully characterize the outcomes in surviving neonates and assess the morbidity and mortality burden. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03101891.
引用
- Miller JL, Baschat AA, Rosner M, et al. Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis: The Renal Anhydramnios Fetal Therapy Trial. JAMA. 2023. PMID: 38051327. doi:10.1001/jama.2023.21153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。